Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07815379
Active, not recruiting Phase 4

Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction

NCT07815379 · tracked via the Priya Life Science Egypt tracker
Sponsor
Mansoura University
Phase
Phase 4
Started
2025-10-12
Last updated
2026-09-11

Condition(s) studied

BPH (Benign Prostatic Hyperplasia)

Investigational drug(s) / intervention(s)

alpha blocker monotherapy Tamsulosinalpha blockers Tamsulosin and Silodosin

alpha blocker monotherapy Tamsulosin: Effect of Tamsulosin and placebo in Management of Lower Urinary Tract Symptoms and Acute Urine Retention in Patients with Benign Prostatic Hyperplasia.

alpha blockers Tamsulosin and Silodosin: BPH patients are given dual alpha blockers compared to single alpha blocker drug

Study summary

Failed medical treatment to alleviate LUTS and AUR is an indication for intervention, some trials were published elucidating the possible use of standard dose tamsulosin and silodosin and double dose tamsulosin but to the best of our knowledge, no studies with head-to-head comparison between Tamsulosin and Combination of Tamsulosin and Silodosin for Management of Lower Urinary Tract Symptoms and Acute Urine Retention in Patients with Benign Prostatic Hyperplasia.

Eligibility

Sex
MALE
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Age ≥40 years. Catheterized patients due to acute urine retention secondary to BPO. Patients with moderate and severe LUTS secondary to BPH as proven by IPSS (International Prostate Symptoms score) ≥8 and Qmax \<15 ml/sec with total void urine volume \>125 cc. Exclusion Criteria: Patients with neurological problems as: uncontrolled DM, parkinsonism and cerebral stroke. Patients with history of previous prostate surgery. Patients with complicated BPH necessitating intervention as: recurrent/persistent UTI, recurrent hematuria, bladder stones and indwelling urethral catheter due to chromic urine retention (CUR). Patients with suspected malignancy by abnormal Digital Rectal Examination (DRE) and or high PSA.

Primary outcome measure(s)

  • IPSS change — 3 months
    IPSS score change at 1 and 3 months following drug adminstration

Trial sites (1)

FacilityCityRegionStatus
Urology and Nephrology Center, Mnasoura University Al Mansurah Dakahlia Governorate

More Mansoura University trials in Egypt

PCNL Versus RIRS for Management of Stones in Solitary Kidney Active, not recruiting
Role of HFNC During FOB in Patients With Respiratory Failure Recruiting
FANS-FURS vs Suction Mini-PCNL for 2-3 cm Renal Stones: A Multicenter Randomized Trial Starting soon
Fully Versus Partially Guided Implants Placement: Measurement of Accuracy of Implant Position and Passivity of Superstructures. Active, not recruiting
Maxillary and Mandibular Nerve Block Recruiting

Other trials for the same condition

Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Feasibility and Safety of a Single Working Element for Bipolar and Laser Enucleation in Prostate Surgery: A Prospective Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07815379 on ClinicalTrials.gov ↗ ← All trials in Egypt